Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018

NCT03582826
ClinicalTrials.gov
MEBO Gut Microbiome Study
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact map@meboresearch.org
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
BannerFans.com
RESEARCH DETAILS

DONATIONS THRU 31-NOV-2016:
£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14

MEBO UK PAYPAL FOR TRINZYME

********
MEBO US PAYPAL FOR TRINZYME

Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Wednesday, June 23, 2010

Email from the makers of Ataluren, in regard to genetic TMAU

In the TMAU research proposal of Dr Christodoulou written a couple of years ago, he suggested PTC124 (now called Ataluren) could be tried on mice to see if it helps with TMAU caused by nonsense mutations. Ataluren is expected to overule the false 'stop' that nonsense mutations produce, while the protein is forming. The protein could then form correctly. It is already in the later stages of testing with genetic disorders such as cystic fibrosis. Normally, nonsense mutations make up a small % of genetic disorders, around 10-15%.

An email was sent to the company involved, PTC Therapeutics, asking if they thought it may someday be a treatement for TMAU caused by nonsense mutations. This was the reply:

Thank you for your email and your interest in ataluren (formerly known as PTC124) and for letting us know about your organization. We are currently conducting a Phase 3 study of ataluren in nonsense mutation cystic fibrosis and a phase 2a study in hemophilia.

Ataluren may have the potential to treat many genetic disorders in which a nonsense mutation is the basis for the disease. If the studies mentioned above yield positive results we hope to conduct clinical studies in additional genetic disorders. We do not have plans to do a trial in trimethylaminuria at this time.

If you would like to be added to our mailing list to receive updates about ataluren, please follow this link to the contact section of our website: http://www.ptcbio.com/5.0_contact_us.aspx . Be sure to check the box "receive PTC updates."
So far, the only side-effects reported seem to be nausea in some cases. More can be read about Ataluren research in pubmed.

Related links:

0 comments:

Post a Comment